Preprint · OA
via OpenAlex
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease
Rawan M. Tarawneh, Denise M Head, Samantha L. Allison, Virginia Buckles, Anne M. Fagan, Jack H. Ladenson, John C. Morris, David M. Holtzman
JAMA Neurology · 2015 · ▲ 96 citations
Abstract
IMPORTANCE: Measures of neuronal loss are likely good surrogates for clinical and radiological disease progression in Alzheimer disease (AD). Cerebrospinal fluid (CSF) markers of neuronal injury or neurodegeneration may offer usefulness in predicting disease progression and guiding outcome assessments and prognostic decisions in clinical trials of disease-modifying therapies. Visinin-like protein 1 (VILIP-1) has demonstrated potential usefulness as a marker of neuronal injury in AD. OBJECTIVE: To investigate the usefulness of CSF VILIP-1, tau, p-tau181, and Aβ42 levels in predicting rates of whole-brain and regional atrophy in early AD and cognitively normal control subjects over time. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal observational study of brain atrophy in participants with early AD and cognitively normal controls. Study participants had baseline CSF biomarker measurements and longitudinal magnetic resonance imaging assessments for a mean follow-up period of 2 to 3 years. Mixed linear models assessed the ability of standardized baseline CSF biomarker measures to predict rates of whole-brain and regional atrophy over the follow-up period. The setting was The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis. Participants (mean age, 72.6 years) were individuals with a clinical diagnosis of very mild AD (n = 23) and cognitively normal controls (n = 64) who were enrolled in longitudinal studies of healthy aging and dementia. The study dates were 2000 to 2010. MAIN OUTCOMES AND MEASURES: Correlations between baseline CSF biomarker measures and rates of whole-brain or regional atrophy in the AD and control cohorts over the follow-up period. RESULTS: Baseline CSF VILIP-1, tau, and p-tau181 levels (but not Aβ42 levels) predicted rates of whole-brain and regional atrophy in AD over the follow-up period. Baseline CSF VILIP-1 levels predicted whole-brain (P = .006), hippocampal (P = .01), and entorhinal (P = .001) atrophy rates at least as well as tau and p-tau181 in early AD. Cognitively normal controls whose CSF VILIP-1, tau, or p-tau181 levels were in the upper tercile had higher rates of whole-brain (P = .02, P = .003, and P = .02, respectively), hippocampal (P = .001, P = .01, and P = .02, respectively), and entorhinal (P = .007, P = .01, and P = .01, respectively) atrophy compared with those whose levels were in the lower 2 terciles. CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid VILIP-1 levels predict rates of whole-brain and regional atrophy similarly to tau and p-tau181 and may provide a useful CSF biomarker surrogate for neurodegeneration in early symptomatic and preclinical AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1001/jamaneurol.2015.0202
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Tarawneh, R.M., Head, D.M., Allison, S.L., Buckles, V., Fagan, A.M., Ladenson, J.H., Morris, J.C., & Holtzman, D.M. (2015). Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. <em>JAMA Neurology</em>. https://doi.org/10.1001/jamaneurol.2015.0202
Vancouver
Tarawneh RM, Head DM, Allison SL, Buckles V, Fagan AM, Ladenson JH, et al. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurology. 2015. doi:10.1001/jamaneurol.2015.0202.
BibTeX
@unpublished{rawan2015Cerebr,
title = {Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease},
author = {Rawan M. Tarawneh and Denise M Head and Samantha L. Allison and Virginia Buckles and Anne M. Fagan and Jack H. Ladenson and John C. Morris and David M. Holtzman},
journal = {JAMA Neurology},
year = {2015},
doi = {10.1001/jamaneurol.2015.0202},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2025
Preprint · CC-BY
Accelerated Epigenetic Aging and Prospective Morbidity and Mortality Among U.S. Veterans
Brain : a journal of neurology 2026
Citation only
Diabetes and neurodegeneration in cognitively unimpaired older adults: implications for cognition.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2020
Open access · CC-BY
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
PLoS ONE 2013
Open access · CC-BY
Characterizing the Role of Brain Derived Neurotrophic Factor Genetic Variation in Alzheimer’s Disease Neurodegeneration
JAMA Neurology 2019
Open access · OA
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Circulation Research 2021
Open access · OA